发明名称 Genotyping tool for improving the prognostic and clinical management of MS patients
摘要 The invention relates to methods of evaluating MS severity based on analysis of single nucleotide polymorphisms (SNPs) and to products and kits for use in such methods. The methods include a method of assessing a multiple sclerosis disease severity phenotype in a human subject having multiple sclerosis, by determining the genotype of the subject at one or more positions of single nucleotide polymorphism (SNP) selected from: rs2107538, rs1137933, rs1318, rs2069763, rs423904, rs876493, rs10243024, rs10259085, rs1042173, rs10492503, rs10492972, rs12047808, rs12202350, rs12861247, rs13353224, rs1350666, rs1555322, rs1611115, rs17641078, rs1805009, rs2028455, rs2032893, rs2049306, rs2066713, rs2074897, rs2076530, rs2187668, rs2213584, rs2227139, rs2234978, rs2239802, rs2395182, rs260461, rs28386840, rs3087456, rs3135388, rs3741981, rs3756450, rs3781202, rs3787283, rs3808585, rs4128767, rs4404254, rs4473631, rs4680534, rs6077690, rs6457594, rs6570426, rs659366, rs6917747, rs7208257, rs7528684, rs7577925, rs762550, rs7956189, rs7995215, rs8049651, rs8702, rs9808753 and rs987107, and/or a SNP in linkage disequilibrium with any one of said SNPs.
申请公布号 US8835111(B2) 申请公布日期 2014.09.16
申请号 US201013255871 申请日期 2010.03.12
申请人 Brainco Biopharma S.L. 发明人 Arteta David;Artieda Marta;Tejedor Diego;Martinez Antonio;Simon Laureano;Crusius Bart A.;Pena Salvador;Sombekke Madeleine;Uitdehaag Bernard;Polman Chris
分类号 C12Q1/68;C12P19/34;A61K39/395 主分类号 C12Q1/68
代理机构 Klarquist Sparkman, LLP 代理人 Klarquist Sparkman, LLP
主权项 1. A method of treating a human subject having multiple sclerosis (MS), the method comprising: obtaining a DNA sample from the subject; detecting in the DNA sample the presence of at least one T allele at single nucleotide polymorphism (SNP) rs2107538, at least one G allele at SNP rs1137933, and at least one A allele at SNP rs1318; correlating the presence of said at least one T allele at SNP rs2107538, at least one G allele at SNP rs1137933, and at least one A allele at SNP rs1318 with an increased MS disease severity, wherein the increased MS disease severity is measured by multiple sclerosis severity score or increased size and/or distribution of T2 brain lesions; and administering an MS therapeutic comprising interferon-beta or glatiramer acetate to the subject when at least one T allele at SNP rs2107538, at least one G allele at SNP rs1137933, and at least one A allele at SNP rs1318 is present.
地址 Derio ES